Neurogene Inc. (NGNE)
Largest Insider Buys in Sector
NGNE Stock Price History Chart
NGNE Stock Performance
About Neurogene Inc.
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Insider Activity of Neurogene Inc.
Over the last 12 months, insiders at Neurogene Inc. have bought $2.72M and sold $0 worth of Neurogene Inc. stock.
On average, over the past 5 years, insiders at Neurogene Inc. have bought $2.72M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Samsara BioCapital GP, LLC (10 percent owner) — $3.78M. McMinn Rachel (Chief Executive Officer) — $969,000. Cvijic Christine Mikail (President and CFO) — $491,400.
The last purchase of 48,770 shares for transaction amount of $1.26M was made by Samsara BioCapital GP, LLC (10 percent owner) on 2024‑11‑26.
List of Insider Buy and Sell Transactions, Neurogene Inc.
| 2024-11-26 | 10 percent owner | 48,770 0.3334% | $25.83 | $1.26M | -12.50% | |||
| 2024-11-22 | Chief Executive Officer | 47,500 0.2565% | $20.40 | $969,000 | +15.81% | |||
| 2024-11-22 | President and CFO | 24,000 0.1301% | $20.48 | $491,400 | +15.81% |